GABAA Modulator I

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H581059

CAS#: 951654-29-8

Description: GABAA Modulator I is novel modulator of the GABAA receptor complex, and in particular for combating anxiety and related diseases.


Chemical Structure

img
GABAA Modulator I
CAS# 951654-29-8

Theoretical Analysis

Hodoodo Cat#: H581059
Name: GABAA Modulator I
CAS#: 951654-29-8
Chemical Formula: C23H21N3O2
Exact Mass: 371.16
Molecular Weight: 371.440
Elemental Analysis: C, 74.37; H, 5.70; N, 11.31; O, 8.61

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: GABAA Modulator I; 3'-(5-(2-Hydroxypropan-2-yl)-1H-benzo[d]imidazol-1-yl)-[1,1'-biphenyl]-2-carboxamide; SCHEMBL1761811; MFCD30186081; AKOS027439948; ZINC117027649

IUPAC/Chemical Name: 2-[3-[5-(2-Hydroxypropan-2-yl)benzimidazol-1-yl]phenyl]benzamide

InChi Key: XOUVTIGDGKTSAA-UHFFFAOYSA-N

InChi Code: InChI=1S/C23H21N3O2/c1-23(2,28)16-10-11-21-20(13-16)25-14-26(21)17-7-5-6-15(12-17)18-8-3-4-9-19(18)22(24)27/h3-14,28H,1-2H3,(H2,24,27)

SMILES Code: O=C(N)C1=CC=CC=C1C2=CC=CC(N3C4=CC=C(C(C)(O)C)C=C4N=C3)=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 371.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Saitow F, Nagano M, Suzuki H. Developmental Changes in Serotonergic Modulation of GABAergic Synaptic Transmission and Postsynaptic GABA(A) Receptor Composition in the Cerebellar Nuclei. Cerebellum. 2018 Jan 19. doi: 10.1007/s12311-018-0922-9. [Epub ahead of print] PubMed PMID: 29349630.

2: Chen J, Li H, Lim G, McCabe MF, Zhao W, Yang Y, Ma W, Li N. Different effects of dexmedetomidine and midazolam on the expression of NR2B and GABAA-α1 following Peripheral Nerve Injury in Rats. IUBMB Life. 2018 Jan 17. doi: 10.1002/iub.1713. [Epub ahead of print] PubMed PMID: 29341457.

3: Zhou X, Zong Y, Zhang R, Zhang X, Zhang S, Wu J, Sun X. Differential Modulation of GABA(A) and NMDA Receptors by an α7-nicotinic Acetylcholine Receptor Agonist in Chronic Glaucoma. Front Mol Neurosci. 2017 Dec 18;10:422. doi: 10.3389/fnmol.2017.00422. eCollection 2017. PubMed PMID: 29326549; PubMed Central PMCID: PMC5741651.

4: Yayeh T, Leem YH, Kim KM, Jung JC, Schwarz J, Oh KW, Oh S. Administration of Alpha(s1)-Casein Hydrolysate Increases Sleep and Modulates GABA(A) Receptor Subunit Expression. Biomol Ther (Seoul). 2018 Jan 9. doi: 10.4062/biomolther.2017.083. [Epub ahead of print] PubMed PMID: 29316237.

5: Artelsmair M, Gu C, Lewis RJ, Elmore CS. Synthesis of C-14 Labeled GABA(A) α2/α3 Selective Partial Agonists and the Investigation of Late-Occurring and Long-Circulating Metabolites of GABA(A) Receptor Modulator AZD7325. J Labelled Comp Radiopharm. 2018 Jan 4. doi: 10.1002/jlcr.3602. [Epub ahead of print] PubMed PMID: 29314165.

6: Bazzurro V, Gatta E, Cupello A, Lange S, Robello M. Antisecretory Factor Modulates GABA(A) Receptor Activity in Neurons. J Mol Neurosci. 2018 Jan 7. doi: 10.1007/s12031-017-1024-8. [Epub ahead of print] PubMed PMID: 29308551.

7: Tschumi CW, Beckstead MJ. Neurotensin speeds inhibition of dopamine neurons through temporal modulation of GABA(A) and GABA(B) receptor-mediated synaptic input. Neuropharmacology. 2018 Jan 4. pii: S0028-3908(18)30004-2. doi: 10.1016/j.neuropharm.2018.01.004. [Epub ahead of print] PubMed PMID: 29307543.

8: Feng HJ, Forman SA. Comparison of αβδ and αβγ GABA(A) receptors: Allosteric modulation and identification of subunit arrangement by site-selective general anesthetics. Pharmacol Res. 2017 Dec 30. pii: S1043-6618(17)31024-1. doi: 10.1016/j.phrs.2017.12.031. [Epub ahead of print] Review. PubMed PMID: 29294355.

9: Neugebauer NM, Miyauchi M, Sato T, Tadano J, Akal H, Ardehali H, Meltzer HY. Hippocampal GABA(A) antagonism reverses the novel object recognition deficit in sub-chronic phencyclidine-treated rats. Behav Brain Res. 2017 Dec 28;342:11-18. doi: 10.1016/j.bbr.2017.12.033. [Epub ahead of print] PubMed PMID: 29289597.

10: Miller SM, Pelly S, Kalanjati VP, Lee A, Colditz PB, Bjorkman ST. Identification and expression of a unique neonatal variant of the GABA(A) receptor α(3) subunit. Brain Struct Funct. 2017 Dec 27. doi: 10.1007/s00429-017-1597-6. [Epub ahead of print] PubMed PMID: 29282556.

11: Montandon G, Wu H, Liu H, Vu MT, Orser BA, Horner RL. δ-Subunit Containing GABA(A) Receptors Modulate Respiratory Networks. Sci Rep. 2017 Dec 22;7(1):18105. doi: 10.1038/s41598-017-17379-x. PubMed PMID: 29273726; PubMed Central PMCID: PMC5741762.

12: Figlerowicz M, Kemnitz P, Mania A, Mazur-Melewska K, Tomczak E, Kuls K, Jończyk-Potoczna K, Graus F, Służewski W. Autoimmune encephalitis with GABA(A) receptor antibodies in a 10-year-old girl. Clin Neurol Neurosurg. 2017 Dec 12;164:160-163. doi: 10.1016/j.clineuro.2017.12.012. [Epub ahead of print] PubMed PMID: 29245105.

13: Liu JP, He YT, Duan XL, Suo ZW, Yang X, Hu XD. Enhanced Activities of δ Subunit-containing GABA(A) Receptors Blocked Spinal Long-term Potentiation and Attenuated Formalin-induced Spontaneous Pain. Neuroscience. 2017 Dec 8;371:155-165. doi: 10.1016/j.neuroscience.2017.12.002. [Epub ahead of print] PubMed PMID: 29229558.

14: Zabela V, Hettich T, Schlotterbeck G, Wimmer L, Mihovilovic MD, Guillet F, Bouaita B, Shevchenko B, Hamburger M, Oufir M. GABA(A) receptor activity modulating piperine analogs: In vitro metabolic stability, metabolite identification, CYP450 reaction phenotyping, and protein binding. J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jan 1;1072:379-389. doi: 10.1016/j.jchromb.2017.11.036. Epub 2017 Dec 2. PubMed PMID: 29227934.

15: Wu XH, Song JJ, Faull RLM, Waldvogel HJ. GABA(A) and GABA(B) receptor subunit localization on neurochemically identified neurons of the human subthalamic nucleus. J Comp Neurol. 2017 Dec 8. doi: 10.1002/cne.24368. [Epub ahead of print] PubMed PMID: 29218727.

16: Kanatani S, Fuks JM, Olafsson EB, Westermark L, Chambers B, Varas-Godoy M, Uhlén P, Barragan A. Voltage-dependent calcium channel signaling mediates GABAA receptor-induced migratory activation of dendritic cells infected by Toxoplasma gondii. PLoS Pathog. 2017 Dec 7;13(12):e1006739. doi: 10.1371/journal.ppat.1006739. eCollection 2017 Dec. PubMed PMID: 29216332; PubMed Central PMCID: PMC5720541.

17: Gagnon M, Bergeron MJ, Perez-Sanchez J, Plasencia-Fernández I, Lorenzo LE, Godin AG, Castonguay A, Bonin RP, De Koninck Y. Reply to The small molecule CLP257 does not modify activity of the K(+)-Cl(-) co-transporter KCC2 but does potentiate GABA(A) receptor activity. Nat Med. 2017 Dec 7;23(12):1396-1398. doi: 10.1038/nm.4449. PubMed PMID: 29216044.

18: Cardarelli RA, Jones K, Pisella LI, Wobst HJ, McWilliams LJ, Sharpe PM, Burnham MP, Baker DJ, Chudotvorova I, Guyot J, Silayeva L, Morrow DH, Dekker N, Zicha S, Davies PA, Holenz J, Duggan ME, Dunlop J, Mather RJ, Wang Q, Medina I, Brandon NJ, Deeb TZ, Moss SJ. The small molecule CLP257 does not modify activity of the K(+)-Cl(-) co-transporter KCC2 but does potentiate GABA(A) receptor activity. Nat Med. 2017 Dec 7;23(12):1394-1396. doi: 10.1038/nm.4442. PubMed PMID: 29216042.

19: Nickolls SA, Gurrell R, van Amerongen G, Kammonen J, Cao L, Brown AR, Stead C, Mead A, Watson C, Hsu C, Owen RM, Pike A, Fish RL, Chen L, Qiu R, Morris ED, Feng G, Whitlock M, Gorman D, van Gerven J, Reynolds DS, Dua P, Butt RP. Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABA(A) receptor positive allosteric modulator PF-06372865. Br J Pharmacol. 2017 Dec 7. doi: 10.1111/bph.14119. [Epub ahead of print] PubMed PMID: 29214652.

20: Chandler CM, Overton JS, Rüedi-Bettschen D, Platt DM. GABA(A) Receptor Subtype Mechanisms and the Abuse-Related Effects of Ethanol: Genetic and Pharmacological Evidence. Handb Exp Pharmacol. 2017 Dec 5. doi: 10.1007/164_2017_80. [Epub ahead of print] PubMed PMID: 29204713.